Identification of Key Gene Targets for Sensitizing Colorectal Cancer to Chemoradiation: an Integrative Network Analysis on Multiple Transcriptomics Data

Author(s):  
Hamed Manoochehri ◽  
Akram Jalali ◽  
Hamid Tanzadehpanah ◽  
Amir Taherkhani ◽  
Massoud Saidijam
2018 ◽  
Vol 20 (6) ◽  
pp. 500-508 ◽  
Author(s):  
Jun-Min Lu ◽  
Yuan-Cheng Chen ◽  
Zeng-Xin Ao ◽  
Jie Shen ◽  
Chun-Ping Zeng ◽  
...  

Medicine ◽  
2020 ◽  
Vol 99 (41) ◽  
pp. e22549
Author(s):  
Mingyan Sheng ◽  
Haofei Tong ◽  
Xiaoyan Lu ◽  
Ni Shanshan ◽  
Xingguo Zhang ◽  
...  

2020 ◽  
Vol 8 (1) ◽  
pp. e001126
Author(s):  
Catherine E Cioffi ◽  
K M Venkat Narayan ◽  
Ken Liu ◽  
Karan Uppal ◽  
Dean P Jones ◽  
...  

IntroductionBody fat distribution is strongly associated with cardiometabolic disease (CMD), but the relative importance of hepatic fat as an underlying driver remains unclear. Here, we applied a systems biology approach to compare the clinical and molecular subnetworks that correlate with hepatic fat, visceral fat, and abdominal subcutaneous fat distribution.Research design and methodsThis was a cross-sectional sub-study of 283 children/adolescents (7–19 years) from the Yale Pediatric NAFLD Cohort. Untargeted, high-resolution metabolomics (HRM) was performed on plasma and combined with existing clinical variables including hepatic and abdominal fat measured by MRI. Integrative network analysis was coupled with pathway enrichment analysis and multivariable linear regression (MLR) to examine which metabolites and clinical variables associated with each fat depot.ResultsThe data divided into four communities of correlated variables (|r|>0.15, p<0.05) after integrative network analysis. In the largest community, hepatic fat was associated with eight clinical biomarkers, including measures of insulin resistance and dyslipidemia, and 878 metabolite features that were enriched predominantly in amino acid (AA) and lipid pathways in pathway enrichment analysis (p<0.05). Key metabolites associated with hepatic fat included branched-chain AAs (valine and isoleucine/leucine), aromatic AAs (tyrosine and tryptophan), serine, glycine, alanine, and pyruvate, as well as several acylcarnitines and glycerophospholipids (all q<0.05 in MLR adjusted for covariates). The other communities detected in integrative network analysis consisted of abdominal visceral, superficial subcutaneous, and deep subcutaneous fats, but no clinical variables, fewer metabolite features (280, 312, and 74, respectively), and limited findings in pathway analysis.ConclusionsThese data-driven findings show a stronger association of hepatic fat with key CMD risk factors compared with abdominal fats. The molecular network identified using HRM that associated with hepatic fat provides insight into potential mechanisms underlying the hepatic fat–insulin resistance interface in youth.


2006 ◽  
Vol 14 (7S_Part_19) ◽  
pp. P1016-P1017
Author(s):  
Burcu F. Darst ◽  
Qiongshi Lu ◽  
Rebecca L. Koscik ◽  
Erin Jonaitis ◽  
Lindsay R. Clark ◽  
...  

2018 ◽  
Vol 60 (5) ◽  
pp. 585-598 ◽  
Author(s):  
Ryo Kimura ◽  
Vivek Swarup ◽  
Kiyotaka Tomiwa ◽  
Michael J. Gandal ◽  
Neelroop N. Parikshak ◽  
...  

2020 ◽  
Vol 13 (S9) ◽  
Author(s):  
Tianyu Zhang ◽  
Liwei Zhang ◽  
Fuhai Li

Abstract Background Though accounts for 2.5% of all cancers in female, the death rate of ovarian cancer is high, which is the fifth leading cause of cancer death (5% of all cancer death) in female. The 5-year survival rate of ovarian cancer is less than 50%. The oncogenic molecular signaling of ovarian cancer are complicated and remain unclear, and there is a lack of effective targeted therapies for ovarian cancer treatment. Methods In this study, we propose to investigate activated signaling pathways of individual ovarian cancer patients and sub-groups; and identify potential targets and drugs that are able to disrupt the activated signaling pathways. Specifically, we first identify the up-regulated genes of individual cancer patients using Markov chain Monte Carlo (MCMC), and then identify the potential activated transcription factors. After dividing ovarian cancer patients into several sub-groups sharing common transcription factors using K-modes method, we uncover the up-stream signaling pathways of activated transcription factors in each sub-group. Finally, we mapped all FDA approved drugs targeting on the upstream signaling. Results The 427 ovarian cancer samples were divided into 3 sub-groups (with 100, 172, 155 samples respectively) based on the activated TFs (with 14, 25, 26 activated TFs respectively). Multiple up-stream signaling pathways, e.g., MYC, WNT, PDGFRA (RTK), PI3K, AKT TP53, and MTOR, are uncovered to activate the discovered TFs. In addition, 66 FDA approved drugs were identified targeting on the uncovered core signaling pathways. Forty-four drugs had been reported in ovarian cancer related reports. The signaling diversity and heterogeneity can be potential therapeutic targets for drug combination discovery. Conclusions The proposed integrative network analysis could uncover potential core signaling pathways, targets and drugs for ovarian cancer treatment.


2015 ◽  
Vol 26 (s1) ◽  
pp. S1985-S1991 ◽  
Author(s):  
Jin Li ◽  
Ying Wang ◽  
Lei Wang ◽  
Hong Liang ◽  
Weixing Feng ◽  
...  

2016 ◽  
Vol 142 ◽  
pp. 45-52 ◽  
Author(s):  
Yong Zeng ◽  
Lan Zhang ◽  
Wei Zhu ◽  
Chao Xu ◽  
Hao He ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document